Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental genetic medicines addressing two rare muscle diseases—one of which has no FDA-approved treatments. Now the ...
On Tuesday, Dyne Therapeutics Inc. (NASDAQ:DYN) announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 ...
The last time I wrote about Dyne Therapeutics (DYN) it was with respect to a Seeking Alpha article entitled "Dyne: H2 2024 Muscle Disease Data Could Boost Value". In this article, I noted about the ...
The last time I wrote about Dyne Therapeutics (DYN) it was with respect to a Seeking Alpha article entitled "Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker". With ...
- All Evaluable Patients in the 3.4 mg/kg Cohort Treated with DYNE-101 Q4W Demonstrated Consistent Splicing Correction with a 19% Mean Improvement Across 22-Gene Panel at 3 Months - - Improvement in ...
Monday, Dyne Therapeutics Inc (NASDAQ:DYN) released clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase 1/2 ...
Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE ...
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday. Shares of Aehr Test Systems (NASDAQ:AEHR) fell sharply during Monday’s session after the company reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results